Dose Dense and Concurrent Trastuzumab for Early Breast Cancer in the Elderly

2011 ◽  
Vol 23 (7) ◽  
pp. 494-495
Author(s):  
U.Y. Cheema ◽  
S. Kalapurakal ◽  
P. White ◽  
A.U. Khan
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
The Elderly ◽  
Dose Dense

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

2021 ◽  
Vol 156 ◽  
pp. 138-148
Author(s):  
Volker Möbus ◽  
Hans-Joachim Lück ◽  
Ekkehart Ladda ◽  
Peter Klare ◽  
Marcus Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Early Breast Cancer ◽  
Randomised Trial ◽  
Phase Iii ◽  
Dose Dense

scholarly journals Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates

Breast Care ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. 447-452 ◽  
Author(s):  
Fernando Kude de Almeida ◽  
Daniela Dornelles Rosa
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Great Variability ◽  
Dose Dense

Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity. According to the Gompertzian model, the smaller tumors are and the more rapid they grow, the more benefit could be expected from dose-dense therapy. Some clinical trials showed reduced mortality when adjuvant chemotherapy is administered in shorter intervals, while others had discordant results. Interpreting results is difficult due to a great variability in doses and schemes used in different trials. Dose-dense chemotherapy does not seem to increase adverse events and appears to be the most efficacious in higher-risk individuals and in hormone receptor-negative tumors. This review intends to summarize the available evidence and recent research about this subject.

Early Breast Cancer in the Elderly

Drugs & Aging ◽  
2008 ◽  
Vol 25 (1) ◽  
pp. 35-45 ◽  
Author(s):  
Gilles Albrand ◽  
Catherine Terret
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
The Elderly

scholarly journals Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer

2019 ◽  
Vol 59 (1) ◽  
pp. 75-81 ◽  
Author(s):  
Antroula Papakonstantinou ◽  
Elham Hedayati ◽  
Mats Hellström ◽  
Hemming Johansson ◽  
Michael Gnant ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Phase Iii ◽  
Phase Iii Study ◽  
Dose Dense

Role of dose-dense chemotherapy in high-risk early breast cancer

2019 ◽  
Vol 31 (6) ◽  
pp. 480-485 ◽  
Author(s):  
Eva Blondeaux ◽  
Francesca Poggio ◽  
Lucia Del Mastro
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Early Breast Cancer ◽  
Dose Dense

Cost effectiveness and tolerability of dose dense versus weekly paclitaxel chemotherapy in patients with early breast cancer: A real-world comparison.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e18264-e18264
Author(s):  
Wanyi Kee ◽  
Raimundas Galiauskas ◽  
Brian Richard Bird ◽  
Kate Murphy ◽  
James Cook ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Real World ◽  
Weekly Paclitaxel ◽  
Dose Dense

scholarly journals HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

2012 ◽  
Vol 10 (1) ◽  
Author(s):  
George Fountzilas ◽  
Christos Valavanis ◽  
Vassiliki Kotoula ◽  
Anastasia G Eleftheraki ◽  
Konstantine T Kalogeras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Breast Cancer Patients ◽  
Sequential Chemotherapy ◽  
Dose Dense
Sign in / Sign up

Export Citation Format

Share Document